Post infarct heart failure: What to do in addition to ACE inhibition
| Autor: | R. W. F. Campbell |
|---|---|
| Rok vydání: | 1994 |
| Předmět: |
medicine.medical_specialty
Heart disease Adrenergic beta-Antagonists Management of heart failure Myocardial Infarction Angiotensin-Converting Enzyme Inhibitors Pharmacotherapy Internal medicine medicine Humans Pharmacology (medical) Heart Failure Pharmacology Aspirin biology business.industry Anticoagulants Angiotensin-converting enzyme General Medicine medicine.disease Surgery Heart failure ACE inhibitor Cardiology biology.protein Myocardial infarction complications Drug Therapy Combination Cardiology and Cardiovascular Medicine business Anti-Arrhythmia Agents medicine.drug |
| Zdroj: | Cardiovascular Drugs and Therapy. 8:115-118 |
| ISSN: | 1573-7241 0920-3206 |
| DOI: | 10.1007/bf00877098 |
| Popis: | ACE (angiotensin converting enzyme) inhibitors are revolutionizing the management of heart failure and are now earning themselves a place in the early treatment of post myocardial infarction (MI) patients who have evidence of left ventricular (LV) dysfunction or, more modestly, evidence of infarct expansion. The aims of ACE inhibitor therapy are to control symptoms, if any, and to improve prognosis. For these indications, they are impressive. Nonetheless, they are not a panacea. Post MI patients face a variety of threats, not least from progression of their underlying ischemic disease, and they should not be denied prognostically advantageous interventions, such as beta-blockers and aspirin. Moreover, ACE inhibitor monotherapy may not be the best management for heart failure itself. The role of other additive agents should not be dismissed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink